Tuesday, November 4, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

T Rowe Price Stock: Mixed Earnings Reveal Deeper Struggles

Robert Sasse by Robert Sasse
August 1, 2025
in Stocks
0
T Rowe Price Stock
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

T. Rowe Price reported mixed second-quarter results, beating earnings expectations with $2.24 per share versus forecasts of $2.13 but missing revenue targets at $1.72 billion, a 0.6% year-over-year decline. The asset manager faced persistent outflows of $14.9 billion, particularly in equity funds ($18.1 billion), though multi-asset strategies saw modest inflows ($0.9 billion). Despite net client withdrawals, assets under management rose 6.9% to $1.68 trillion, driven by $125.4 billion in market gains. However, rising costs (up 6.5% to $1.25 billion) squeezed operating income, which plummeted 15.3% to $478.3 million, while fee margins eroded from 41.1 to 39.6 basis points.

ETFs Offer Limited Relief

The ETF division emerged as a bright spot, attracting $6.7 billion in inflows and growing assets to $16.2 billion, with 11 funds surpassing $500 million. Yet, this segment remains too small to offset broader challenges. Only 35% of U.S. funds outperformed peers over one year, and just 22% beat passive strategies. The stock dipped 0.44% premarket, reflecting investor skepticism about the firm’s ability to counter industry fee pressures and shifting client preferences.

Ad

T Rowe Price Stock: Buy or Sell?! New T Rowe Price Analysis from November 4 delivers the answer:

The latest T Rowe Price figures speak for themselves: Urgent action needed for T Rowe Price investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 4.

T Rowe Price: Buy or sell? Read more here...

Tags: T Rowe Price
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Royal Gold Stock
Stocks

Royal Gold Shares Surge to Record High on Acquisition Momentum

September 29, 2025
Unitedhealth Stock
Stocks

UnitedHealth Shares Present Conflicting Outlook for Investors

September 29, 2025
ASML Stock
Stocks

ASML Forges Strategic AI Alliance to Bolster Semiconductor Dominance

September 29, 2025
Next Post
Adobe Stock

Adobe Stock: Regulatory Blockade Backfires Spectacularly

Rackspace Technology Stock

Rackspace Technology Stock: Climate Goals Boost Competitive Edge

Strategy Stock

Strategy Stock: Bitcoin Bet Fuels Stunning Turnaround

Recommended

Mitek Stock

Mitek Shares: Technical Excellence Meets Valuation Concerns

2 months ago
Empowering Remote Regions: the Nano Grid Technology for Reliable Electricity Solutions

FTC Solar Reports Mixed Q4 Financial Results with Focus on Future Growth

2 years ago
Kratos Defense, Security Stock

Kratos Defense Shares Face Investor Skepticism Amid Hypersonic Breakthrough

2 weeks ago
Finance_ People trading stocks

Goldman Sachs Analyst Maintains Neutral Rating on Boise Cascade with Increased Price Target

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Alarm Shares Approach Critical Support Level Amid Steep Decline

GEO Group Stock: Will Earnings Spark a Reversal?

FirstCash Shares Surge Following Exceptional Quarterly Performance

MarketAxess Shares Approach Critical Juncture Ahead of Earnings

Balchem’s Breakthrough Nutrient Formula Shows Superior Absorption in Clinical Trials

Lancaster Colony Surpasses Quarterly Projections with Strong Q1 2026 Results

Trending

HealthEquity Stock
Analysis

HealthEquity Stock Poised for Growth Amid Regulatory Shifts and Strategic Expansion

by Felix Baarz
November 4, 2025
0

Market analysts are turning increasingly bullish on HealthEquity as the company benefits from favorable regulatory developments and...

Coherus BioSciences Stock

Coherus BioSciences Approaches Critical Financial Milestone

November 4, 2025
Aurora Innovation Stock

Aurora Innovation Shares Plunge to New Low Amid Sector Challenges

November 4, 2025
Alarm Stock

Alarm Shares Approach Critical Support Level Amid Steep Decline

November 4, 2025
GEO Stock

GEO Group Stock: Will Earnings Spark a Reversal?

November 4, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • HealthEquity Stock Poised for Growth Amid Regulatory Shifts and Strategic Expansion
  • Coherus BioSciences Approaches Critical Financial Milestone
  • Aurora Innovation Shares Plunge to New Low Amid Sector Challenges

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com